The contribution of mouse models to our understanding of systemic candidiasis

FEMS Microbiology Letters

Volumn 320, Issue 1, 2011, Pages 1-8

  Szabo, Edina K ^a   MacCallum, Donna M ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Candida; Gastrointestinal; Immunity; Intravenous; Mouse; Therapy

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; DECTIN 1; EFUNGUMAB; GREEN FLUORESCENT PROTEIN; INTERLEUKIN 12; INTERLEUKIN 6; NEUTRALIZING ANTIBODY; PATTERN RECOGNITION RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRIAZOLE; TUMOR NECROSIS FACTOR ALPHA;

ANTIFUNGAL ACTIVITY; BACTERIUM ISOLATE; BLOOD CULTURE; CANDIDA ALBICANS; DISEASE ACTIVITY; DISEASE COURSE; DISEASE MODEL; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESISTANCE; ENZYME RELEASE; EXPERIMENTAL MOUSE; FUNGAL CELL; FUNGAL COLONIZATION; FUNGAL VIRULENCE; FUNGUS GROWTH; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENETIC ASSOCIATION; GLUCONEOGENESIS; HOST SUSCEPTIBILITY; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; INVASIVE CANDIDIASIS; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SHORT SURVEY; TISSUE SPECIFICITY;

ANIMALS; CANDIDA; CANDIDIASIS; DISEASE MODELS, ANIMAL; HUMANS; MICE; VIRULENCE;

BACTERIA (MICROORGANISMS); CANDIDA; CANDIDA ALBICANS;

EID: 79957902458     PISSN: 03781097     EISSN: 15746968     Source Type: Journal    
DOI: 10.1111/j.1574-6968.2011.02262.x     Document Type: Short Survey

References (63)

1. Andes D (2005) Use of an animal model of disseminated candidiasis in the evaluation of antifungal therapy. Methods Mol Med 118: 111-128.
2. Andes D, Lepak A, Pitula A, Marchillo K & Clark J (2005) A simple approach for estimating gene expression in Candida albicans directly from a systemic infection site. J Infect Dis 192: 893-900.
3. Andes D, Lepak A, Nett J, Lincoln L & Marchillo K (2006) In vivo fluconazole pharmacodynamics and resistance development in a previously susceptible Candida albicans population examined by microbiologic and transcriptional profiling. Antimicrob Agents Ch 50: 2384-2394.
4. Arendrup M, Horn T & Frimodt-Moller N (2002) In vivo pathogenicity of eight medically relevant Candida species in an animal model. Infection 30: 286-291.
5. Ashman RB, Bolitho EM & Papadimitriou JM (1993) Patterns of resistance to Candida albicans in inbred mouse strains. Immunol Cell Biol 71: 221-225.
6. Ashman RB, Fulurija A & Papadimitriou JM (1996) Strain-dependent differences in host response to Candida albicans infection in mice are related to organ susceptibility and infectious load. Infect Immun 64: 1866-1869.
7. Ashman RB, Vijayan D & Wells CA (2011) IL-12 and related cytokines: function and regulatory implications in Candida albicans infection. Clin Dev Immunol 2011: 686597.
8. Asmundsdottir LR, Erlendsdottir H, Agnarsson BA & Gottfredsson M (2009) The importance of strain variation in virulence of Candida dubliniensis and Candida albicans: results of a blinded histopathological study of invasive candidiasis. Clin Microbiol Infec 15: 576-585.
9. Barelle CJ, Manson CL, MacCallum DM, Odds FC, Gow NA & Brown AJ (2004) GFP as a quantitative reporter of gene regulation in Candida albicans. Yeast 21: 333-340.
10. Barelle CJ, Priest CL, Maccallum DM, Gow NA, Odds FC & Brown AJ (2006) Niche-specific regulation of central metabolic pathways in a fungal pathogen. Cell Microbiol 8: 961-971.
11. Bendel CM, Hess DJ, Garni RM, Henry-Stanley M & Wells CL (2003) Comparative virulence of Candida albicans yeast and filamentous forms in orally and intravenously inoculated mice. Crit Care Med 31: 501-507.
12. Bougnoux ME, Diogo D, Francois N, Sendid B, Veirmeire S, Colombel JF, Bouchier C, Van Kruiningen H, d'Enfert C & Poulain D (2006) Multilocus sequence typing reveals intrafamilial transmission and microevolutions of Candida albicans isolates from the human digestive tract. J Clin Microbiol 44: 1810-1820.
13. Brieland J, Essig D, Jackson C, Frank D, Loebenberg D, Menzel F, Arnold B, DiDomenico B & Hare R (2001) Comparison of pathogenesis and host immune responses to Candida glabrata and Candida albicans in systemically infected immunocompetent mice. Infect Immun 69: 5046-5055.
14. Brown AJ, Odds FC & Gow NA (2007) Infection-related gene expression in Candida albicans. Curr Opin Microbiol 10: 307-313.
15. Cabezas J, Albaina O, Montanez D, Sevilla MJ, Moragues MD & Ponton J (2010) Potential of anti-Candida antibodies in immunoprophylaxis. Immunotherapy 2: 171-183.
16. Castillo L, MacCallum DM, Brown AJ, Gow NA & Odds FC (2011) Differential regulation of kidney and spleen cytokine responses in mice challenged with pathology-standardized doses of Candida albicans mannosylation mutants. Infect Immun 79: 146-152.
17. Chamilos G, Lionakis MS, Lewis RE & Kontoyiannis DP (2007) Role of mini-host models in the study of medically important fungi. Lancet Infect Dis 7: 42-55.
18. Clemons KV, Gonzalez GM, Singh G, Imai J, Espiritu M, Parmar R & Stevens DA (2006) Development of an orogastrointestinal mucosal model of candidiasis with dissemination to visceral organs. Antimicrob Agents Ch 50: 2650-2657.
19. de Repentigny L, Phaneuf M & Mathieu LG (1992) Gastrointestinal colonization and systemic dissemination by Candida albicans and Candida tropicalis in intact and immunocompromised mice. Infect Immun 60: 4907-4914.
20. Enjalbert B, Maccallum DM, Odds FC & Brown AJ (2007) Niche-specific activation of the oxidative stress response by the pathogenic fungus Candida albicans. Infect Immun 75: 2143-2151.
21. Field LH, Pope LM, Cole GT, Guentzel MN & Berry LJ (1981) Persistence and spread of Candida albicans after intragastric inoculation of infant mice. Infect Immun 31: 783-791.
22. Gibbons DL & Spencer J (2011) Mouse and human intestinal immunity: same ballpark, different players; different rules, same score. Mucosal Immunol 4: 148-157.
23. Herrera C & Guentzel MN (1982) Mice with persistent gastrointestinal Candida albicans as a model for antifungal therapy. Antimicrob Agents Ch 21: 51-53.
24. Jiang X, Shen C, Yu H, Karunakaran KP & Brunham RC (2010) Differences in innate immune responses correlate with differences in murine susceptibility to Chlamydia muridarum pulmonary infection. Immunology 129: 556-566.
25. Koh AY, Kohler JR, Coggshall KT, Van Rooijen N & Pier GB (2008) Mucosal Damage and neutropenia are required for Candida albicans dissemination. PLoS Pathog 4: e35.
26. Kusne S, Tobin D, Pasculle AW, Van Thiel DH, Ho M & Starzl TE (1994) Candida carriage in the alimentary tract of liver transplant candidates. Transplantation 57: 398-402.
27. Lionakis MS, Lim JK, Lee CC & Murphy PM (2011) Organ-specific innate immune responses in a mouse model of invasive candidiasis. J Innate Immun 3: 180-199.
28. Louria DB, Brayton RG & Finkel G (1963) Studies on the pathogenesis of experimental Candida albicans infections in mice. Sabouraudia 2: 271-283.
29. MacCallum DM (2009) Massive induction of innate immune response to Candida albicans in the kidney in a murine intravenous challenge model. FEMS Yeast Res 9: 1111-1122.
30. MacCallum DM (2010) Candida infections and modelling disease. Pathogenic Yeasts, The Yeast Handbook (Ashbee HR & Bignell E, eds), pp. 41-67. Springer-Verlag, New York, NY.
31. MacCallum DM & Odds FC (2002a) Efficacy of parenteral itraconazole against disseminated Candida albicans infection in two mouse strains. J Antimicrob Chemoth 50: 225-229.
32. MacCallum DM & Odds FC (2002b) Influence of grapefruit juice on itraconazole plasma levels in mice and guinea pigs. J Antimicrob Chemoth 50: 219-224.
33. MacCallum DM & Odds FC (2005) Temporal events in the intravenous challenge model for experimental Candida albicans infections in female mice. Mycoses 48: 151-161.
34. MacCallum DM, Castillo L, Brown AJP, Gow NAR & Odds FC (2009a) Early-expressed chemokines predict kidney immunopathology in experimental disseminated Candida albicans infections. PLoS ONE 4: e6420.
35. MacCallum DM, Castillo L, Nather K, Munro CA, Brown AJ, Gow NA & Odds FC (2009b) Property differences among the four major Candida albicans strain clades. Eukaryot Cell 8: 373-387.
36. MacCallum DM, Coste A, Ischer F, Jacobsen MD, Odds FC & Sanglard D (2010) Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection. Antimicrob Agents Ch 54: 1476-1483.
37. Marquis G, Montplaisir S, Pelletier M, Auger P & Lapp WS (1988) Genetics of resistance to infection with Candida albicans in mice. Brit J Exp Pathol 69: 651-660.
38. Matthews RC, Rigg G, Hodgetts S, Carter T, Chapman C, Gregory C, Illidge C & Burnie J (2003) Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90. Antimicrob Agents Ch 47: 2208-2216.
39. Mellado E, Cuenca-Estrella M, Regadera J, Gonzalez M, Diaz-Guerra TM & Rodriguez-Tudela JL (2000) Sustained gastrointestinal colonization and systemic dissemination by Candida albicans, Candida tropicalis and Candida parapsilosis in adult mice. Diagn Microbiol Infect Dis 38: 21-28.
40. Mencacci A, Cenci E, Bistoni F, Bacci A, Del Sero G, Montagnoli C, Fe d'Ostiani C & Romani L (1998) Specific and non-specific immunity to Candida albicans: a lesson from genetically modified animals. Res Immunol 149: 352-361; discussion 517-519.
41. Miranda LN, van der Heijden IM, Costa SF, Sousa AP, Sienra RA, Gobara S, Santos CR, Lobo RD, Pessoa VP Jr & Levin AS (2009) Candida colonisation as a source for candidaemia. J Hosp Infect 72: 9-16.
42. Morrell M, Fraser VJ & Kollef MH (2005) Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Ch 49: 3640-3645.
43. Netea MG & Marodi L (2010) Innate immune mechanisms for recognition and uptake of Candida species. Trends Immunol 31: 346-353.
44. Nichterlein T, Buchheidt D, Hein A, Becker KP, Mosbach K & Kretschmar M (2003) Comparison of glucan detection and galactomannan enzyme immunoassay in gastrointestinal and systemic murine candidiasis. Diagn Microbiol Infect Dis 46: 103-108.
45. Odds FC, Davidson AD, Jacobsen MD, Tavanti A, Whyte JA, Kibbler CC, Ellis DH, Maiden MC, Shaw DJ & Gow NA (2006) Candida albicans strain maintenance, replacement, and microvariation demonstrated by multilocus sequence typing. J Clin Microbiol 44: 3647-3658.
46. Ostrosky-Zeichner L, Rex JH, Pappas PG et al. (2003) Antifungal susceptibility survey of 2, 000 bloodstream Candida isolates in the United States. Antimicrob Agents Ch 47: 3149-3154.
47. Papadimitriou JM & Ashman RB (1986) The pathogenesis of acute systemic candidiasis in a susceptible inbred mouse strain. J Pathol 150: 257-265.
48. Park S, Kelly R, Kahn JN et al. (2005) Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Ch 49: 3264-3273.
49. Pope LM, Cole GT, Guentzel MN & Berry LJ (1979) Systemic and gastrointestinal candidiasis of infant mice after intragastric challenge. Infect Immun 25: 702-707.
50. Rehli M (2002) Of mice and men: species variations of Toll-like receptor expression. Trends Immunol 23: 375-378.
51. Sandovsky-Losica H, Barr-Nea L & Segal E (1992) Fatal systemic candidiasis of gastrointestinal origin: an experimental model in mice compromised by anti-cancer treatment. J Med Vet Mycol 30: 219-231.
52. Sanglard D & Odds FC (2002) Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis 2: 73-85.
53. Savage DC & Dubos RJ (1967) Localization of indigenous yeast in the murine stomach. J Bacteriol 94: 1811-1816.
54. Scanlan PD & Marchesi JR (2008) Micro-eukaryotic diversity of the human distal gut microbiota: qualitative assessment using culture-dependent and -independent analysis of faeces. ISME J 2: 1183-1193.
55. Skrzypek MS, Arnaud MB, Costanzo MC, Inglis DO, Shah P, Binkley G, Miyasato SR & Sherlock G (2010) New tools at the Candida Genome Database: biochemical pathways and full-text literature search. Nucleic Acids Res 38: D428-D432.
56. Spellberg B, Johnston D, Phan QT, Edwards JE Jr, French SW, Ibrahim AS & Filler SG (2003) Parenchymal organ, and not splenic, immunity correlates with host survival during disseminated candidiasis. Infect Immun 71: 5756-5764.
57. Spellberg B, Ibrahim AS, Edwards JE Jr & Filler SG (2005) Mice with disseminated candidiasis die of progressive sepsis. J Infect Dis 192: 336-343.
58. Spellberg BJ, Ibrahim AS, Avanesian V, Fu Y, Myers C, Phan QT, Filler SG, Yeaman MR & Edwards JE Jr (2006) Efficacy of the anti-Candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis. J Infect Dis 194: 256-260.
59. Sugar AM & Liu XP (2000) Effect of grapefruit juice on serum voriconazole concentrations in the mouse. Med Mycol 38: 209-212.
60. Tsoni SV, Kerrigan AM, Marakalala MJ, Srinivasan N, Duffield M, Taylor PR, Botto M, Steele C & Brown GD (2009) Complement C3 plays an essential role in the control of opportunistic fungal infections. Infect Immun 77: 3679-3685.
61. Uno K, Sugiura S, Konishi M, Yasuda Y, Mikasa K & Kita E (2007) Evaluation of diagnostic methods for Candida albicans translocation in a mouse model: seminested polymerase chain reaction, blood culture, and serological assays. J Infect Chemother 13: 196-203.
62. Wagner RD, Vazquez-Torres A, Jones-Carson J, Warner T & Balish E (1996) B cell knockout mice are resistant to mucosal and systemic candidiasis of endogenous origin but susceptible to experimental systemic candidiasis. J Infect Dis 174: 589-597.
63. Wingard JR, Dick JD, Merz WG, Sandford GR, Saral R & Burns WH (1982) Differences in virulence of clinical isolates of Candida tropicalis and Candida albicans in mice. Infect Immun 37: 833-836.